Skip to main content

Table 2 General characteristics of included studies (about the relationships between Nestin expression and OS or PFS in glioma patients)

From: Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis

First author Year Origin country No. of patients Median/mean age (year) WHO grade Detect method Cut off level Survival end points Follow up period Survival analysis Adjusted variables
Hatanpa [19] 2014 USA 50 median 37.5 years (20–66) II–III IHC median OS 4.3 year multivariate (KM) nestin, IDH, WHO grade, oligodendroglioma component (astrocytoma or oligoastrocytoma), MIB-1, age, sex, extent of resection and type of adjuvant, therapy
Milde [20] 2012 Russia 379 NR II–III IHC 50 % OS median 53 months multivariate cytogenetic group only, or cytogenetic group and posterior fossa group
         PFS    
wan [21] 2011 Germany 283 NR II–IV IHC median OS Mean 11.21 ± 4.26 years multivariate WHO grade, patient age at diagnosis and extent of resection
Kim [12] 2011 Korea 88 mean 54.9 years (13–80) IV IHC 50 % OS mean 13.9 (1–53) months multivariate age, sex, KPS, extent of removal, chemoradiotherapeutic modality, temozolomide modality, after temozolomide therapy and stem cell marker expression
         PFS    
Arai [22] 2012 Japan 64 median 55 years (11–79) III–IV IHC 60 % OS 1–67 months KM NR
Dahlrot [18] 2014 Denmark 25 NR II IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
         PFS    
Dahlrot [18] 2014 Denmark 26 NR III IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status
         PFS    
Dahlrot [18] 2014 Denmark 185 NR IV IF median OS Media 12 months multivariate age, performance status (PS) and IDH1 status